Bellicum Announces Data Presentations on Lead Product Candidate BPX-501 and CAR-T and TCR Pipeline Programs at the 57th American Society of Hematology (ASH) Annual Meeting
Seven abstracts accepted including oral presentation on the Company’s controllable CAR-T product candidate BPX-401
Investor/Analyst Luncheon
Bellicum will also host an investor and analyst luncheon on
Full List of ASH Presentations on Bellicum Programs
BPX-501:
Poster Presentation: “Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Results of a Phase I-II Trial”
- Abstract Number: 1931
- Session Name: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I
-
Date:
Saturday, December 5, 2015 -
Presentation Time:
5:30 PM - 7:30 PM EST
Poster Presentation: “Immune Reconstitution after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Phenotypic and Functional Results of a Phase I-II Trial”
- Abstract Number: 3093
- Session Name: 703. Adoptive Immunotherapy: Poster II
-
Date:
Sunday, December 6, 2015 -
Presentation Time:
6:00 PM - 8:00 PM EST
Poster Presentation: “BPX-501 Cells (donor T cells transduced with iC9 suicide gene) Are Able to Clear Life-Threatening Viral Infections in Children with Primary Immune Deficiencies Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT)”
- Abstract Number: 4299
- Session Name: 703. Adoptive Immunotherapy: Poster III
-
Date:
Monday, December 7, 2015 -
Presentation Time:
6:00 PM - 8:00 PM EST
Additional data on more BPX-501 patients to be presented at ASH.
BPX-401:
Oral Presentation: “Expression of MyD88/CD40 Drives In Vivo Activation and Proliferation of Chimeric Antigen Receptor-Modified T Cells That Can be Effectively Regulated By Inducible Caspase-9”
- Abstract Number: 851
- Session Name: 703. Adoptive Immunotherapy: Preclinical Studies
-
Date:
Monday, December 7, 2015 -
Presentation Time:
5:30 PM EST
BPX-601:
Poster Presentation: “Inducible MyD88/CD40 Allows Rimiducid-Dependent Activation to Control Proliferation and Survival of Chimeric Antigen Receptor-Modified T Cells”
- Abstract Number: 4295
- Session Name: 703. Adoptive Immunotherapy: Poster III
-
Date:
Monday, December 7, 2015 -
Presentation Time:
6:00 PM - 8:00 PM EST
Enhanced TCRs:
Poster Presentation: “Inducible MyD88/CD40 Enhances Proliferation and Survival of PRAME-Specific TCR-Engineered T Cells and Increases Anti-Tumor Effects in Myeloma”
- Abstract Number: 1886
- Session Name: 703. Adoptive Immunotherapy: Poster I
-
Date:
Saturday, December 5, 2015 -
Presentation Time:
5:30 PM - 7:30 PM EST
Bellicum Program Licensed from
Poster Presentation: “T Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies”
- Abstract Number: 3002
- Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
-
Date:
Sunday, December 6, 2015 -
Presentation Time:
6:00 PM - 8:00 PM EST
About
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151105005490/en/
Source:
Investors:
Bellicum Pharmaceuticals
Alan Musso, CFO
832-384-1116
amusso@bellicum.com
or
Media:
BMC
Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com